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BACKGROUND: Outcome after renal transplantation 
in children has been variable. We undertook a ret-
rospective study of our experience over the past five 
years. 
STUDY DESIGN: From January 1, 1988, to October 
15, 1992, 60 renal transplantations were performed 
upon 59 children at the Children's Hospital of Pitts-
burgh. Twenty-eight (47 percent) of the kidneys were 
from cadaveric donors. and 32 (53 percent) were from 
living donors. The recipients ranged in age from 0.8 
to 17.4 years. with a mean of 9.8 ± 4.8 years. Forty-six 
(77 percent) recipients were undergoing a first trans-
plant, while 14 (23 percent) received a second or 
third transplant. Eight (13 percent) of the patients 
were sensitized. with a panel reactive antibody of more 
than 40 percent. Eleven of the 14 patients undergoing 
retransplantation and seven of the eight patients who 
were sensitized received kidneys from cadaveric donors. 
Thirty-three (55 percent) patients received cyclospor-
ine-based immunosuppression, and 27 (45 percent) 
received FK506 as the primary immunosuppressive 
agent. 
RESULTS: The median follow-up period was 36 months, 
with a range of six to 63 months. The one- and 
four-year actuarial patient survival rate was 100 and 
98 percent. The one- and four-year actuarial graft 
survival rate was 98 and 83 percent. For living donor 
recipients. the one- and four-year actuarial patient sur-
vival rate was 100 and 100 percent: for cadaveric 
recipients. it was 100 and 96 percent. Corresponding 
one- and four-year actuarial graft survival rates were 
100 and 95 percent for the living donor recipients 
and 96 and 69 percent for the cadaveric recipients. 
Patients on cyclosporine had a one- and four-year 
patient survival rate of 100 and 97 percent. and pa-
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tients on FK506 had a one- and three-year patient 
survival rate of 100 and 100 percent. Corresponding 
one- and four-year actuarial graft survival rates were 
100 and 85 percent in the cyclosporine group, while 
one- and three-year actuarial graft survival rates were 
96 and 84 percent in the FK506 group. 
The mean serum creatinine level was 1.24 ± 0.64 
mg per dL; the blood urea nitrogen level was 26 ± 13 
mg per dL. The incidence of rejection was 47 percent; 
75 percent of the rejections were steroid-responsive. 
The incidence of cytomegalovirus was 10 percenL The 
incidence of post-transplant lymphoproliferative dis-
order was 8 percent. None of the patients on cy-
closporine were able to be taken off prednisone; 56 
percent of the patients receiving FK506 were taken 
off prednisone successfully. Early growth and devel-
opment data suggest that the patients receiving FK506 
off prednisone had significant gains in growth. 
CONCLUSIONS: These results support the idea that 
renal transplantation is a successful therapy for end-
stage renal disease in children. They also illustrate 
the potential benefits of a new immunosuppressive 
agent, FK506. J. Am. Coil. Surg., 1994. 179 424-432. 
THE RESlUS after renal transplantation in pediatric 
patients have been \·ariable. wirh some centers 
describing bir results and others reporting ex-
cellent outcomes (1. :!). ;\ recent multicenter 
report. combining data from most of the major 
pediatric centers in the C nited States of America. 
showed one-year patient survival rates of 96 and 
92 percent for living related and cadaveric re-
cipients. and one-year graft slIn;val rates of 88 
and 71 percenl. respectively t:\). We reviewed 
our own experience during a Ih'e-vear period 
with both living related and cadaveric transplan-
tation. and examined the ettect of different im-
munosuppressive agents. speciticallv FK506 . 
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Between Januarv 1. 1988 and October 15, 1992. 
60 consecutive patients unden,'ent renal trans-
plantation onlv at the Children's Hospital of Pitts-
burgh (Table I). Children undergoing concomi-
tant or previous hepatic transplantation were 
excluded from analysis. Thirty-two (53 percent) 
patients received kidneys from living donors. 
These were parents in 30 instances. one grand-
mother, and one adoptive bther. Twenty-eight 
(47 percent) patients received cadaveric kidne\·s. 
The mean recipient age was 9.8 ± 4.8 Years. with 
a range of 0.8 to 17.4 Years. Five (8 percent) 
recipients were less than:! years of age: 12 (:!O 
percent) were less than 5. Forty-six (77 percent) 
recipients were undergoing a first transplant. 
while I,t (:!3 percent) received a second or third 
transplant. Eight (1:3 percent) patients were sen-
sitized. with a panel reactive antibody (PRA) 01 
more than 40 percent. Elevell of the 14 patiems 
lIndergoing retransplantation and seyen of the 
eight patients who were sensitized received kid-
ne\'s from cadaveric donors. Thirtv-three (55 per-
cellt) pa tien ts received c\'clospori ne-hased imlllu-
nosuppression. and 2i (45 percent) received 
FK50() as the priman' immunosuppressive agenl. 
The causes of end-stage renal disease are listed 
ill Table II. 
(\closporille-based immunosuppression in the 
~l Ii\'ing related cases was done with induction 
\1 illlH'sota an tilymphoblast globulin (\ L\LG l. :!O 
Illg per kg per day. tor :! \\'t'eks: Imuran-. Bur-
roughs \\'clkome. Research Triangle Park. :\C 
,azathioprine) and Dellasone . L·p-john. Kalama-
mo. \11 (prednisone) I,'ert' IIsed from the ()IIISl'1. 
"hile Sandimll1une-. Sando!. I'harmacellticals. 
East HanO\'ef. :'\.J (C\'C'losporine l was hegun one 
\\'t,t'k postoperativel\'. at a dost' of :-) Illg per kg 
twice daily. In (he U cadavenc cases Irealen with 
('\'c/osporine. azathioprine was Ilsed ill I I pa-
tients. induction OKT3 (:1 mg per da\' for two 
weeks) was lIsed in tour cases. and induction 
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MALG was used in one case. In the 27 patients 
receiving FK506 (12 living donor instances and 
15 cadaveric instances). an intravenous dose of 
n.l mg per kg per dav was begun postoperatively 
as a continuous infusion. The oral dose was begun 
at 0.15 mg per kg twice daily. ,-vathioprine. :! 
to 3 mg per kg per dav. was used initially ill 
ten (36 percent) patients. and steroids were given 
to all patients. 
STATISTICAL ANALYSIS 
The standard two-sample I test was lIsed to 
test differences between means. ",hill' differences 
in proportiolls were tested \Ising Pearson's chi-
square test of association. The Wilcoxon rank 
slim tcst. a non parametric eqlli\'alent to the stand-
ard two-sample I test. was used II)\' highly skewed 
data. 
Patient slIrvival was calculated lrom the date 
01 renal transplantation unlil death. and graft 
survival was calculated lrom t he date of renal 
transplantation until graft failure. retransplanta-
tion. O\' patielll death. Suryi\'al curves were gen-
erated IIsing (he Kaplan-Meier (product-limit) 
method and were compared using the general-
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FIG. 1. Patient sun;val. C.ldaveric versus h\;ng related donurs. 
5 
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FIr.. 2. Patient sun;val. Patients treated with cvclosporine versus FK506. 
il.ed Wilcoxon (Breslow) test. All tests were two 
tailed .. \ p value less of than 0.05 was considered 
statisticallv significant. 
year actuarial patient survival rate was 100 and 
98 percent. One male. 5.7 years old at the time 
of a second cadaveric transplant under cyclospor-
ine. died with a functioning kidnev 19 months 
postoperativelv. as a result of complications re-
lated to idiopathic hypertrophic subaortic steno-
sis. In cadaveric recipients. the one- and four-year 
actuarial patient smvival rate was 100 and 96 
RESULTS 
The median follow-up period was 36 months 
(range of six to 63 months). The one- and four-
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FIG. 3. Graft survival. Cadaveric versus living related donors. 
FIG. 4. Graft survival. Patients treated with cvclosporine versus FK506. 
percent: in living donor instances, the one- and 
four-year actuarial patient survival rate was 100 
and 100 percent. Patients treated with cvclospor-
ine had a one- and four-year actuarial patient 
survival rate of 100 and 97 percent. Patients 
treated with FK506 had a one- and three-year 
actuarial patient survival rate of 100 and 100 
percent. respectively (Figs. 1 and 2). 
The overall one- and four-year actuarial graft 
survival rate was 98 and 83 percent; 100 and 
95 percent in the living related patients and 96 
and 69 percent in the cadaveric group. Patients 
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FIG. 6. Serum creatinine. Patients treated with c\'c1osponne verslIs FK506. 
recei\ing cyclosporine had a one- and four·vear 
actuarial graft sunival rate of 100 and 85 percent. 
(Fig. ~~FK Patients treated with FIG06 had a shorter 
follow-up period. Their one- and three-vear ac-
tuarial graft survival rates were 96 and 84 percent 
(Fig . .f). In addition to the one late mortality, 
five additional patients have lost grafts: two to 
noncompliance 1.8 and 3.2 years after transplan-
tation (both being treated with cyclosporine), one 
to recurrent hemolytic uremic s\ndrome within 
the tirst week after transplantation (treated with 
FK506: the first graft of this child treated with 
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Fie, H, Serum blood urea nitrogen. Cadaveric versus living related donors. 
cvclosporine was also lost to recurrent hemolvtic 
uremic syndrome in the first postoperative week), 
one to recurrent focal segmental glomerulo-
sclerosis J.S ,'ears post-transplantation (treated 
widl C\'closporine initiallv). and one to recurrent 
membranoproliferative glomerulonephritis 2.4 
years post-transplantation (treated with FK506; 
the first transplant for the patient was also lost 
LO recurrem disease. treated with cvclosporine 
therapy). 
Parameters of renal fUllction over time, strati-
tied bv type of transplam (cadaveric or living 
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donor). immunosuppressive agent (cyclosporine 
or FK506). or age (less than or greater than 
five years of age at the time of the transplant) 
are given in Table III and in Figures 5-10. The 
mean serum creatinine level (representing the 
most recent value) for all patients was 1.24 ±O.64 
mg per dL. The calculated creatinine clearance 
was :~U±OS mL per minute (4, 5). The mean 
blood urea nitrogen level was 26±13 mg per 
dL. :-.Jo differences were seen between living do-
llor or. cadaveric recipients, or bet\veen patients 
treated with cydosporine or FK506. for anv of 
these values. The mean serum creatinine level 
for recipients less than the age of five years was 
signiiicantlv lower than for the patients five years 
or older. but the calculated creatinine clearances 
were not significantly different. 
The incidence of rejection in the living related 
group was :H percent (ten of :tl patients); in 
the cadaveric group, it was 64 percent (18 of 
28 patients) (p=O.021)' Patients receiving cydo-
sporine had an incidence of rejection of 39 per-
cent (13 of 33 patients); 15 percent (five of 33 
patients) required OKT3. In patients receiving 
FK506. rejection was seen in 56 percent of the 
patienrs (15 of 27 patients): 7 percent (t\'/o of 
27 patients) required OKT3 (p=O.293). 
The acute tubular necrosis rate was 5 percent: 
zero percent in the living related group and 11 
percent in the cadaveric group (p=O.058). Two 
patients required dialysis in the postoperative pe-
riod, one each on cydosporine and FK506. 
Fifteen (56 percent) patients receiving FK506 
were successfullv taken off prednisone. Three ad-
ditional patients were taken otf prednisone but 
experienced late rejection and took steroids. No 
patient on cvclosporine had prednisone perma-
nentl\' halted. although one patient was off for 
nearly 15 months (p<O.OOOOl). 
Cvtomegalovirus (C:VIV) infection was seen in 
six patients (10 percent) and was treated with 
Cytovene V, Syntex Laboratories. Inc., Palo Alto, 
CA (gancyclovir). There were three (11 percent) 
patients receiving kidneys from cadavers and 
three (9 percent) patients receiving kidneys from 
living related donors. Of the six patients with 
CMV. one C~ percent) was treated with cyclospor-
ine, and five ( 19 percent) were treated with FK506 
(p=(UH7). Five of these six were seronegative 
recipients of seropositive kidneys. :-.Jo patient had 
CMV pneulllonia. and none required admission 
to the illtensive care llnit. 
There were five (H percent) instances of post-
transplant lvmphoproliferative disorder (PTLD) , 
three (11 percent) in cadaveric recipients, two 
(6 percent) ill living donor recipients, one (3 
percent) ill ;t patient treated with cydosporine. 
and f(Hlr (15 percent) in patients treated with 
FK506 (p=O.lOO). All patients had resolution of 
the PTLD with cessation or diminution of im-
munosuppression. and all kept their graft. There 
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was one additional instance of adenopathv with 
pulmonary nodules that did not show PTLD on 
biopsy, but that did respond to a reduction in 
immunosuppression. 
There were three patients converted from cy-
closporine to FK506, one for rejection and two 
for proteinuria. The child with rejection was suc-
cessfullv rescued. and one child with proteinuria 
had a significant decrease in protein excretion. 
The other patient eventually lost the kidney to 
recurrent focal segmental glomerulosclerosis. 
There was one arterial pseudoaneurysm that 
required operative repair. one arterial stenosis 
that responded to balloon dilatation. and one 
arterial leak that required repair. There were 
two ureteral complications. one leak requiring 
repair and one stenosis requiring revision of the 
ureteroneocvstostomy. The technical complica-
tion rate was thus 8 percent. 
DISCUSSION 
The patients in this group were not selected. 
\\11ile most were good risk. low PRA patients. 
there were also some high risk patients. Several 
patients weighed less than 10 kg. Some patients. 
particularlv those with a high PRA. had been 
reterred from other centers for retransplantation. 
In general. all groups of patients did reasonably 
well. regardless of the source of the kidney or 
the immunosuppressive agent. The living donor 
patients had less rejection and seem to have had 
better long-term graft survival rates. The patients 
receiving FK506 required less prednisone. The 
ability to discontinue prednisone in many of the 
patients receiving FK506 has important implica-
tions for long-term growth after transplantation, 
and there is preliminary evidence suggesting im-
proved growth in the patients receiving FK506 
who are not taking steroids (6). Our experience 
with adult transplantation has indicated that there 
is a learning curve associated with using FK506 
in renal transplantation (7). \\llile patient and 
graft survival rates were comparable in the pe-
diatric patients receiving cyclosporine and FK506, 
there were more CMV infections and a trend 
toward more PTLD in the FK506 group. Fortu-
nately, these complications all resolved with re-
duction in the immunosuppression and appro-
priate antiviral therapy. 
We believe that there are several factors that 
have contributed to these results. The patients 
were maintained in optimal medical condition 
bv their nephrologists before transplantation. 
There was a low initial acute tubular necrosis 
rate, even in the cadaveric group. Onlv two pa-
tients required dialvsis after transplantation. Les-
sons learned from our much larger experience 
with adult renal transplantation have had a sig-
nificant role-pediatric transplan t patients ac-
count for only about 7 percent of the total num-
ber of renal transplants performed at the 
University of Pittsburgh. 
Our data suggest that renal transplantation is 
t 
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a successful therapy for end-stage renal disease 
in children. Further work should accentuate ways 
of limiting the long-term side effects of chronic 
immunosuppression. ~ewer agents. such as 
FK506. with its steroid-eliminating capability. may 
be useful in achieving that goal. 
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